INTRODUCTION
Psoriasis is a common chronic inflammatory skin condition affecting about 1% to 2% of the general population in the United States and United Kingdom. 1, 2 The disease is characterized by abnormal and increased growth of the cells that produce keratin and abnormal functioning of the immune system, especially T lymphocytes. 3 It may be triggered by several factors such as stress, alcohol consumption, drugs, smoking, sunlight, infections, local trauma, endocrine factors and genetic changes. 4 Psoriasis can be identified in different clinical presentations or subtypes, including nail psoriasis, palmoplantar psoriasis, psoriatic arthritis, plaque psoriasis, psoriatic erythroderma and generalized pustular psoriasis. 5 Around 20% of patients are diagnosed with severe types of the disease. 6 There is no difference in prevalence between the sexes, although it is more common in adults than in children. 1 It may be presented in association with a variety of comorbidities such as arthritis, depression and cardiovascular diseases. 7 It can lead to fear of other reactions and social isolation, thus affecting the patients' quality of life. 8 There continues to be no cure for psoriasis. 9 There are different options for treatments that can be used alone or in combination, such as systemic drugs, topical drugs and phototherapy. 10 In decision-making, physicians need to consider the disease severity, the patients' circumstances and the best evidence available. 11 The aim of this review was to identify and summarize the evidence from Cochrane systematic reviews (SRs) relating to interventions for treating psoriasis.
OBJECTIVE
To synthesize the evidence from Cochrane SRs regarding interventions for treating psoriasis. 
Inclusion criteria

Types of study
We only included SRs published in the Cochrane Database of Systematic Reviews. We excluded all protocols for SRs and withdrawn SRs. We also did not take previous versions of a single SR into consideration, or SRs that were being updated. We did not apply any date limit as an inclusion criterion.
Types of participants
The participants included were patients (regardless of age) who had been diagnosed with any form of psoriasis. SRs considering participants presenting psoriatic arthritis with no skin involvement were not included.
Types of intervention
We considered SRs assessing any intervention (whether pharmacological or not), which could either be single interventions or be in combination with other interventions, compared with any other intervention, an inactive comparator or no intervention (no treatment).
Types of outcomes
We considered any outcome (clinical or laboratory), as evaluated in the SRs that were included.
Search for reviews
We conducted a broad search in the Cochrane Database of Systematic Reviews (via Wiley) on June 17, 2018. The full search strategy is presented in Table 1 .
Selection of reviews
Two authors (RLP and DVP) screened the titles and abstracts independently. Any disagreements were resolved by consulting a third author (ALCM). The SRs that met the inclusion criteria were selected and summarized by three authors (COCL, RR, RLP).
Presentation of results
We used a qualitative synthesis (narrative approach) to present the results from the search and from the SRs that were included.
RESULTS
Search results
Our search strategy retrieved 124 references. After screening the titles and abstracts, six systematic reviews were selected for fulltext assessment. [12] [13] [14] [15] [16] [17] During this selection phase, two SRs were excluded because they were very outdated versions of two reviews that are currently being updated. 18, 19 Thus, we included six SRs for qualitative synthesis, given that they fulfilled our eligibility criteria.
Reviews included
We present a summary of each SR that was considered. Details regarding the characteristics of the interventions, comparisons,
outcomes and the quality of evidence are presented in Table 2 . in Cochrane Reviews NA = not assessed; PASI = Psoriasis Area and Severity Index; PASI 75 = 75% reduction in the PASI index; NB-UVB = narrow-band ultraviolet B; PUVA = psoralen ultraviolet A photochemotherapy. *GRADE (Grading of Recommendations Assessment, Development and Evaluation) aims to assess the quality of the evidence. Outcomes are classified as providing the following: (a) high quality of evidence (high confidence that the estimated effect is near the true effect); (b) moderate quality of evidence (it is very likely that the estimated effect is close to the real effect but there is a possibility that it is not); (c) low quality of evidence (limited confidence in the effect estimate); or (d) very low quality of evidence (the true effect is likely to be substantially different from the estimated effect). 
Anti-tumor necrosis factor agents for treating pediatric psoriasis
Interventions for treating nail psoriasis
This review 13 evaluated the efficacy and safety of the treatments for nail psoriasis and included 18 RCTs with 1,266 participants.
It was not possible to pool the results because of the heterogeneity of many of the studies. The findings regarding the main outcome of improvement in nail score are presented below:
• Infliximab (5 mg/kg) was superior to placebo after medium-term treatment (57.2% improvement in nail score versus -4.1%; P < 0.001) and short-term treatment;
• Golimumab (50 mg and 100 mg) was superior to placebo after medium-term treatment (33% improvement in nail score versus 0% and 54% versus 0%, respectively; P < 0.001) and shortterm treatment.
• Superficial radiotherapy (SRT) was superior to placebo after short-term treatment (20% improvement in nail score versus 0%; P = 0.03).
• Ciclosporin was similar to etretinate.
• Methotrexate was similar to ciclosporin.
• Ustekinumab was similar to placebo.
• 5-fluorouracil (1%) in Belanyx lotion as a vehicle was similar to Belanyx lotion alone.
• Tazarotene (0.1% cream) was similar to clobetasol propionate.
• Calcipotriol (50 μg/g) was similar to betamethasone dipropionate with salicylic acid.
• Calcipotriol (0.005%) was similar to betamethasone dipropionate.
Not all the studies included reported adverse events; those that did only reported mild adverse effects. Only one study reported the effect on quality of life, which limits the confidence in the results. In the comparison between NB-UVB and oral PUVA for treating chronic plaque psoriasis, there was no statistical difference between the groups regarding the proportions of the participants reaching 75% reduction in PASI (RR 0.91; 95% CI 0.63 to 1.32; one RCT; 51 participants; low quality of evidence). There was also no difference regarding the outcome of dropping out due to side effects (RR 0.71; 95% CI 0.20 to 2.54; three RCTs; 247 participants; low quality of evidence).
In the comparison between NB-UVB and bath PUVA for patients with chronic plaque psoriasis, the only outcome reported was the clearance rate (clearance was defined as no lesions of psoriasis or minimal residual activity). The clearance rate in studies that made comparisons between patients was significantly better in the bath PUVA group (RR 0.18; 95% CI 0.05 to 0.71; one RCT; 36 participants; low quality of evidence).
In the comparison between NB-UVB and topical PUVA for treating palmoplantar psoriasis, there was no statistical difference in the clearance rate (RR 0.09; 95% 0.01 to 1.56; one RCT; 50 participants; low quality of evidence).
In the comparison between NB-UVB and selective broad-band ultraviolet B for treating chronic plaque psoriasis, there was also no difference in the clearance rate (RR 1.40; 95% CI 0.92 to 2.13; one RCT; 100 participants; low quality of evidence). Nor was there any difference regarding dropping out due to side effects (RR 3.0; 95% CI 0.32 to 27.87; one RCT; 100 participants; low quality of evidence).
In the comparison of combined therapy of NB-UVB plus retinoid versus PUVA plus retinoid for patients with chronic plaque guttate psoriasis, there was also no difference in the clearance rate (RR 0.93; 95% CI 0.79 to 1.10; two RCTs; 90 participants; low quality of evidence). Nor was there any difference regarding the proportion of patients reaching 75% reduction in PASI (RR 0.89; 95% 0.59 to 1.35; 60 participants; one RCT; low quality of evidence).
The authors of this review concluded that the current evidence was heterogenous and needed to be interpreted with caution. All the evidence presented was from head-to-head comparisons and no inactive comparator was considered. The overall quality of the evidence was low because of imprecision and risk of bias.
Further studies are imperative in order to confirm the efficacy and safety of these interventions for psoriasis.
For further details, refer to the original abstract, available from http://cochranelibrary-wiley.com/doi/10.1002/14651858.
CD009481.pub2/full.
Oral fumaric acid esters for treating psoriasis
This review 15 The authors of this SR also performed many analyses on corticosteroids alone or in combination with vitamin D compounds.
In general, most corticosteroid interventions performed better then placebo, but this statement is not accurate for all corticosteroids. Each analysis needs to be considered when assessing the relevance of this intervention for treating chronic plaque psoriasis.
Many head-to-head comparisons were also included, and these data may be assessed in the full version of the SR. This SR did not include any evaluation of the quality of the evidence using the GRADE recommendations.
For further details and access to all the analyses, refer to the original abstract, available from http://cochranelibrary-wiley.com/ doi/10.1002/14651858.CD005028.pub3/full.
Topical treatments for treating scalp psoriasis
This SR 17 had the aim of evaluating all topical interventions for scalp psoriasis. Because of this wide eligibility criterion, 59 RCTs (11,561 participants) were included. In total, 15 comparisons were assessed. In this summary, we only report the following three comparisons, which the authors of this SR considered to be the "main • Proportion of patients discontinuing due to adverse events: ). Only one SR limited the population criterion, through only including pediatric patients. 12 The fact that some SRs used broad criteria for interventions resulted in inclusion of a high number of randomized clinical trials (RCTs). Therefore, there was high diversity of populations, interventions and outcomes, and multiple analysis had to be performed. This should be taken into consideration, in making recommendations for practice.
The number of systematic reviews published over the years has also been increasing. A rapid search of the literature, using the term "Psoriasis" [Mesh] and a filter for systematic reviews retrieved 5,310 abstracts from MEDLINE. The number of studies published per year since 1963 is presented in Figure 1 .
This high number of published papers is a rough estimate.
However, this volume of data does not necessarily mean that the quality of the data on interventions for treating psoriasis is good. Table 2 may provide a guide for clinical practice, but all healthcare decision-makers and patients need to be aware that future studies could produce drastically changed results, in relation to the current studies.
Regarding research implications, further studies are needed in order to reduce the uncertainties surrounding the effects from several interventions for treating psoriasis. The reporting on all RCTs needs to follow the recommendations of the Consolidated Standards for Reporting Trials (CONSORT). 25 All studies need to be well designed and well conducted, in order to reduce imprecision and the risk of bias.
CONCLUSION
This review included six Cochrane systematic reviews that pro- 
